Flexion Therapeutics Inc (FLXN) was Initiated by Lake Street to “Buy” and the brokerage firm has set the Price Target at $38. Lake Street advised their investors in a research report released on Jul 21, 2016.
Many Wall Street Analysts have commented on Flexion Therapeutics Inc. Flexion Therapeutics Inc was Resumed by Wells Fargo to “Outperform” on May 3, 2016.
Flexion Therapeutics Inc opened for trading at $15.4 and hit $16.02 on the upside on Wednesday, eventually ending the session at $15.9, with a gain of 3.65% or 0.56 points. The heightened volatility saw the trading volume jump to 1,87,654 shares. Company has a market cap of $343 M.
In a different news, on Jun 16, 2016, C Ann Merrifield (director) purchased 1,000 shares at $13.39 per share price. According to the SEC, on May 23, 2016, Michael D. Clayman (CEO) purchased 2,000 shares at $10.40 per share price. On May 20, 2016, Neil Bodick (Chief Medical Officer) purchased 850 shares at $10.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Flexion Therapeutics Inc. is a specialty pharmaceutical company focused on the development and commercialization of injectable pain therapies. The Company is also focused on anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions such as osteoarthritis (OA) a type of degenerative arthritis. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum from moderate to severe pain. The Company’s products include FX006 which is indicated for front line intra-articular (IA) therapy for patients with moderate to severe OA pain; FX007 which is indicated for post-operative pain and FX005 which is indicated for end-stage OA pain. The Company is conducting a pivotal Phase IIb clinical trial of FX006. The Company is conducting preclinical local pharmacology and toxicology experiments of FX007. FX005 has completed its Phase IIa trials.